Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions

International Journal of Clinical Practice

Volumn 62, Issue 1, 2008, Pages 27-38

  Staskin, D R ^a,f   Rosenberg, M T ^b   Dahl, N V ^c   Polishuk, P V ^d   Zinner, N R ^e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Mid Michigan Health Centers Jackson   (United States)

^c Watson Laboratories Inc   (United States)

^d Palomar Urology   (United States)

^e Western Clinical Research   (United States)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYBUTYNIN; TOLTERODINE;

ABDOMINAL PAIN; ADULT; AGED; APPLICATION SITE REACTION; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DYSURIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; OVERACTIVE BLADDER; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSTATE DISEASE; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SEX DIFFERENCE; SEX RATIO; STATISTICAL SIGNIFICANCE; SYMPTOM; URINE RETENTION; VALIDATION STUDY; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; HEALTH STATUS INDICATORS; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 37349063037     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01625.x     Document Type: Article

References (37)

1. Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001 87 : 760 6.
2. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 20 : 327 36.
3. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984 132 : 474 9.
4. Irwin DE, Milsom I, Kopp Z et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006 97 : 96 100.
5. Temml C, Heidler S, Ponholzer A, Madersbacher S. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol 2005 48 : 622 7.
6. Zakaria L, Anastasiadis AG, Shabsigh R. Common conditions of the aging male: erectile dysfunction, benign prostatic hyperplasia, cardiovascular disease and depression. Int Urol Nephrol 2001 33 : 283 92.
7. Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002 8 : S608 15.
8. Kelleher CJ, Cardozo L, Chapple CR et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005 95 : 81 5.
9. Roehrborn CG, Abrams P, Rovner ES et al. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int 2006 97 : 1003 6.
10. Kaplan SA, Roehrborn CG, Dmochowski R et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006 68 : 328 32.
11. Jumadilova Z, Harris H, del Aguila M et al. Agent Selection for Overactive Bladder Patients with and without Documented Comorbid Benign Prostatic Hyperplasia. Presented at the International Continence Society 35th Annual Meeting. Montreal, QC, 2005.
12. Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid Program. Value Health 2005 8 : 495 505.
13. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003 326 : 841 7.
14. McConnell J, Abrams P, Khoury S et al. for the International Scientific Committee 2005) Evaluation and treatment of lower urinary tract symptoms (LUTS) in older men. In : McConnell S, Abrams P, Denis L et al., eds. Proceedings from the 6th International Consultation on New Developments in Prostate Cancer and Prostate Diseases, 24-27 June. Paris, France : Health Publications, pp. 387 401.
15. Kaplan SA, Roehrborn CG, Rovner ES et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006 296 : 2319 28.
16. Lee JY, Kim HW, Lee SJ et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004 94 : 817 20.
17. Davila GW, Daugherty CA, Sanders SW, for the Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001 166 : 140 5.
18. Dmochowski RR, Sand PK, Zinner NR et al. for the Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003 62 : 237 42.
19. Appell RA, Chancellor MB, Zobrist RH et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003 78 : 696 702.
20. Dmochowski RR, Davila GW, Zinner NR et al. for the Transdermal Oxybutynin Study Group. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002 168 : 580 6.
21. Dmochowski RR, Nitti V, Staskin D et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005 23 : 263 70.
22. Sand P, Zinner N, Newman D et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007 99 : 836 44.
23. Sand PK, Goldberg RP, Dmochowski RR et al. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of TRansdermal therapy In overactive bladder with oXybutynin trial. Am J Obstet Gynecol 2006 195 : 1730 5.
24. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006 49 : 1079 86.
25. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997 104 : 1374 9.
26. Kobelt G, Kirchberger I, Malone-Lee J. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999 83 : 583 90.
27. Kelleher CJ, Pleil AM, Reese PR et al. How much is enough and who says so? The case of the King's Health Questionnaire and overactive bladder. BJOG 2004 111 : 605 12.
28. Beck AT, Ward CH, Mendelson M et al. An inventory for measuring depression. Arch Gen Psychiatry 1961 4 : 561 71.
29. Dmochowski R, Abrams P, Marschall-Kehrel D et al. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 2007 51 : 1054 64.
30. Pleil AM, Reese PR, Kelleher CJ, Okano GJ. Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. Health Econ Prev Care 2001 2 : 69 75.
31. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006 175 : 999 1004.
32. Abrams P, Cardozo L, Fall M et al. for the Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002 21 : 167 78.
33. Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 2006 68 (Suppl. 2A 3 8.
34. European Agency for the Evaluation of Medicinal Products and Committee for Proprietary Medicinal Products. Note for Guidance on the Clinical Investigation of Medicinal Products for the Treatment of Urinary Incontinence. London, UK, 2002. http://www.emea.europa.eu/pdfs/human/ewp/001801en.pdf (accessed 3 August 2007).
35. Okamura K, Usami T, Nagahama K, Maruyama S, Mizuta E. 'Quality of life' assessment of urination in elderly Japanese men and women with some medical problems using International Prostate Symptom Score and King's Health Questionnaire. Eur Urol 2002 41 : 411 9.
36. Okamura K, Usami T, Nagahama K, Maruyama S, Mizuta E. The relationships among filling, voiding subscores from International Prostate Symptom Score and quality of life in Japanese elderly men and women. Eur Urol 2002 42 : 498 505.
37. Rosenberg MT, Staskin DR, Kaplan SA et al. A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract 2007 61 : 1535 46 (OnlineEarly Articles).